ABSTRACT
PURPOSE: We present a new method for identifying the absolute location (i.e., relative to the optic disc) of the preferred retinal location (PRL) simultaneously for the two eyes of patients with central vision loss. For this, we used a binocular eye-tracking system that determines the pupillary axes of both eyes without a user calibration routine. METHODS: During monocular viewing, we measured the pupillary axis and the angle between it and the visual axis (angle Kappa) for 10 eyes with normal vision. We also determined their fovea location relative to the middle of the optic disc with the MP-1 microperimeter. Then, we created a transformation between the eye-tracking and microperimeter measurements. We used this transformation to predict the absolute location of the monocular and binocular PRLs of nine patients with central vision loss. The accuracy of the monocular prediction was evaluated with the microperimeter. The binocular PRLs were checked for retinal correspondence and functionality by placing them on fundus photographs. RESULTS: The transformation yielded an average error for the monocular measures of 0.2 (95% confidence interval, 1.0 to -0.6 degrees) horizontally and 0.5 (95% confidence interval, 1.1 to -0.1 degrees) vertically. The predicted binocular measures showed that the PRLs were generally in corresponding locations in the two eyes. One patient whose PRLs were not in corresponding positions complained about diplopia. For all patients, at least one PRL fell onto functional retina during binocular viewing. CONCLUSIONS: This study shows that measurements of the location of the binocular PRLs relative to the pupillary axes can be transformed into absolute locations.
Subject(s)
Retina/physiopathology , Scotoma/physiopathology , Vision, Binocular/physiology , Visual Field Tests , Visual Fields/physiology , Adult , Aged , Aged, 80 and over , Calibration , Female , Fovea Centralis , Humans , Male , Middle Aged , Pupil/physiology , Visual Field Tests/methodsABSTRACT
Modeling the heterogeneity of the tumor microenvironment (TME) in vitro is essential to investigating fundamental cancer biology and developing novel treatment strategies that holistically address the factors affecting tumor progression and therapeutic response. Thus, the development of new tools for both in vitro modeling, such as patient-derived organoids (PDOs) and complex 3D in vitro models, and single cell omics analysis, such as single-cell RNA-sequencing, represents a new frontier for investigating tumor heterogeneity. Specifically, the integration of PDO-based 3D in vitro models and single cell analysis offers a unique opportunity to explore the intersecting effects of interpatient, microenvironmental, and tumor cell heterogeneity on cell phenotypes in the TME. In this review, the current use of PDOs in complex 3D in vitro models of the TME is discussed and the emerging directions in the development of these models are highlighted. Next, work that has successfully applied single cell analysis to PDO-based models is examined and important experimental considerations are identified for this approach. Finally, open questions are highlighted that may be amenable to exploration using the integration of PDO-based models and single cell analysis. Ultimately, such investigations may facilitate the identification of novel therapeutic targets for cancer that address the significant influence of tumor-TME interactions.
Subject(s)
Neoplasms , Humans , Biology , Organoids , Phenotype , Single-Cell Analysis , Tumor MicroenvironmentABSTRACT
The spatial configuration of cells in the tumor microenvironment (TME) affects both cancer and fibroblast cell phenotypes contributing to the clinical challenge of tumor heterogeneity and therapeutic resistance. This is a particular challenge in stroma-rich pancreatic ductal adenocarcinoma (PDAC). Here, a versatile system is described to study the impact of tissue architecture on cell phenotype using PDAC as a model system. This fully human system encompassing both primary pancreatic stellate cells and primary organoid cells using the TRACER platform to allow the creation of user-defined TME architectures that have been inferred from clinical PDAC samples and are analyzed by CyTOF to characterize cells extracted from the system. High dimensional characterization using CyTOF demonstrates that tissue architecture leads to distinct hypoxia and proliferation gradients. Furthermore, phenotypic markers for both cell types are also graded in ways that cannot be explained by either hypoxia or coculture alone. This demonstrates the importance of using complex models encompassing cancer cells, stromal cells, and allowing control over architecture to explore the impact of tissue architecture on cell phenotype. It is anticipated that this model will help decipher how tissue architecture and cell interactions regulate cell phenotype and hence cellular and tissue heterogeneity.
Subject(s)
Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Humans , Coculture Techniques , Pancreatic Neoplasms/metabolism , Carcinoma, Pancreatic Ductal/pathology , Phenotype , Tumor Microenvironment , Pancreatic NeoplasmsABSTRACT
Complex 3D bioengineered tumour models provide the opportunity to better capture the heterogeneity of patient tumours. Patient-derived organoids are emerging as a useful tool to study tumour heterogeneity and variation in patient responses. Organoid cultures typically require a 3D microenvironment that can be manufactured easily to facilitate screening. Here we set out to create a high-throughput, "off-the-shelf" platform which permits the generation of organoid-containing engineered microtissues for standard phenotypic bioassays and image-based readings. To achieve this, we developed the Scaffold-supported Platform for Organoid-based Tissues (SPOT) platform. SPOT is a 3D gel-embedded in vitro platform that can be produced in a 96- or 384-well plate format and enables the generation of flat, thin, and dimensionally-defined microgels. SPOT has high potential for adoption due to its reproducible manufacturing methodology, compatibility with existing instrumentation, and reduced within-sample and between-sample variation, which can pose challenges to both data analysis and interpretation. Using SPOT, we generate cultures from patient derived pancreatic ductal adenocarcinoma organoids and assess the cellular response to standard-of-care chemotherapeutic compounds, demonstrating our platform's usability for drug screening. We envision 96/384-SPOT will provide a useful tool to assess drug sensitivity of patient-derived organoids and easily integrate into the drug discovery pipeline.
Subject(s)
Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Humans , Organoids/pathology , Carcinoma, Pancreatic Ductal/pathology , Pancreatic Neoplasms/pathology , Drug Evaluation, Preclinical/methods , Drug Discovery , Tumor MicroenvironmentABSTRACT
A major barrier to the successful application of nanotechnology for cancer treatment is the suboptimal delivery of therapeutic payloads to metastatic tumor deposits. We previously discovered that cabozantinib, a tyrosine kinase inhibitor, triggers neutrophil-mediated anticancer innate immunity, resulting in tumor regression in an aggressive PTEN/p53-deficient genetically engineered murine model of advanced prostate cancer. Here, we specifically investigated the potential of cabozantinib-induced neutrophil activation and recruitment to enhance delivery of BSA-coated polymeric nanoparticles (BSA-NPs) into murine PTEN/p53-deficient prostate tumors. On the basis of the observation that BSA coating of NPs enhanced association and internalization by activated neutrophils by approximately 6-fold in vitro, relative to uncoated NPs, we systemically injected BSA-coated, dye-loaded NPs into prostate-specific PTEN/p53-deficient mice that were pretreated with cabozantinib. Flow cytometric analysis revealed an approximately 4-fold increase of neutrophil-associated BSA-NPs and an approximately 32-fold increase in mean fluorescent dye uptake following 3 days of cabozantinib/BSA-NP administration, relative to BSA-NP alone. Strikingly, neutrophil depletion with Ly6G antibody abolished dye-loaded BSA-NP accumulation within tumors to baseline levels, demonstrating targeted neutrophil-mediated intratumoral NP delivery. Furthermore, we observed an approximately 13-fold decrease in accumulation of BSA-NPs in the liver, relative to uncoated NPs, post-cabozantinib treatment, suggesting that BSA coating of NPs can significantly enhance cabozantinib-induced, neutrophil-mediated targeted intratumoral drug delivery, while mitigating off-target toxicity. Collectively, we demonstrate a novel targeted nano-immunotherapeutic strategy for enhanced intratumoral delivery of BSA-NPs, with translational potential to significantly augment therapeutic indices of cancer medicines, thereby overcoming current pharmacologic barriers commonly encountered in preclinical/early-phase drug development.
Subject(s)
Anilides/therapeutic use , Nanoparticles/metabolism , Neutrophils/metabolism , Prostatic Neoplasms/drug therapy , Pyridines/therapeutic use , Receptor Protein-Tyrosine Kinases/therapeutic use , Anilides/pharmacology , Animals , Disease Models, Animal , Humans , Male , Mice , Pyridines/pharmacology , Receptor Protein-Tyrosine Kinases/pharmacologyABSTRACT
The precision of the delivery of therapeutics to the desired injection site by syringes and hollow needles typically depends on the operator. Here, we introduce a highly sensitive, completely mechanical and cost-effective injector for targeting tissue reliably and precisely. As the operator pushes the syringe plunger, the injector senses the loss-of-resistance on encountering a softer tissue or a cavity, stops advancing the needle and delivers the payload. We demonstrate that the injector can reliably deliver liquids to the suprachoroidal space-a challenging injection site that provides access to the back of the eye-for a wide range of eye sizes, scleral thicknesses and intraocular pressures, and target sites relevant for epidural injections, subcutaneous injections and intraperitoneal access. The design of this simple and effective injector can be adapted for a broad variety of clinical applications.
Subject(s)
Drug Delivery Systems/instrumentation , Drug Delivery Systems/methods , Injections/instrumentation , Injections/methods , Animals , Drug Delivery Systems/adverse effects , Equipment Design/instrumentation , Equipment Design/methods , Eye/pathology , Humans , Infusion Pumps/adverse effects , Injections/adverse effects , Injections, Epidural/instrumentation , Injections, Epidural/methods , Injections, Intraperitoneal/instrumentation , Injections, Intraperitoneal/methods , Injections, Subcutaneous/instrumentation , Injections, Subcutaneous/methods , Needles , Rabbits , Syringes , Wounds and InjuriesABSTRACT
Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial patients across several malignancies. Here, we show that cabozantinib rapidly eradicates invasive, poorly differentiated PTEN/p53-deficient murine prostate cancer. This was associated with enhanced release of neutrophil chemotactic factors from tumor cells, including CXCL12 and HMGB1, resulting in robust infiltration of neutrophils into the tumor. Critically, cabozantinib-induced tumor clearance in mice was abolished by antibody-mediated granulocyte depletion or HMGB1 neutralization or blockade of neutrophil chemotaxis with the CXCR4 inhibitor plerixafor. Collectively, these data demonstrate that cabozantinib triggers a neutrophil-mediated anticancer innate immune response, resulting in tumor clearance.Significance: This study is the first to demonstrate that a tyrosine kinase inhibitor can activate neutrophil-mediated antitumor innate immunity, resulting in invasive cancer clearance. Cancer Discov; 7(7); 750-65. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 653.
Subject(s)
Anilides/administration & dosage , Chemokine CXCL12/antagonists & inhibitors , HMGB1 Protein/antagonists & inhibitors , PTEN Phosphohydrolase/genetics , Prostatic Neoplasms/drug therapy , Pyridines/administration & dosage , Tumor Suppressor Protein p53/genetics , Animals , Benzylamines , Cell Line, Tumor , Cell Proliferation/drug effects , Chemokine CXCL12/genetics , Cyclams , HMGB1 Protein/genetics , Heterocyclic Compounds/administration & dosage , Humans , Immunity, Innate/drug effects , Male , Mice , Neutrophils/drug effects , Prostatic Neoplasms/genetics , Prostatic Neoplasms/immunology , Prostatic Neoplasms/pathology , Protein Kinase Inhibitors/administration & dosage , Tumor Microenvironment/geneticsABSTRACT
Cdc42 is a Rho-GTPase which plays a major role in regulating cell polarity and migration by specifying the localization of filopodia. However, the role of Cdc42 in GBM invasion has not been thoroughly investigated. We generated stable doxycycline-inducible clones expressing wild type (WT)-, constitutively active (CA)-, and dominant negative (DN)-Cdc42 in three different human glioma cell lines. Expression of CA-Cdc42 significantly increased the migration and invasive properties of malignant glioma cells compared to WT and DN-Cdc42 cell clones, and this was accompanied by a greater number of filopodia and focal adhesion structures which co-localize with phosphorylated focal adhesion kinase (FAK). By mass spectrometry and immunoprecipitation studies, we demonstrated that activated Cdc42 binds to IQGAP1. When implanted orthotopically in mice, the CA-Cdc42 expressing glioma cells exhibited enhanced local migration and invasion, and led to larger tumors, which significantly reduced survival. Using the Cancer Genome Atlas dataset, we determined that high Cdc42 expression is associated with poorer progression free survival, and that Cdc42 expression is highest in the proneural and neural subgroups of GBM. In summary, our studies demonstrate that activated Cdc42 is a critical determinant of the migratory and invasive phenotype of malignant gliomas, and that its effect may be mediated, at least in part, through its interaction with IQGAP1 and phosphorylated FAK.
Subject(s)
Glioblastoma/metabolism , Neoplasm Invasiveness , cdc42 GTP-Binding Protein/metabolism , Animals , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Cell Adhesion , Cell Line, Tumor , Cell Movement , Cell Survival , Disease Progression , Disease-Free Survival , Doxycycline/chemistry , Focal Adhesion Kinase 1/metabolism , Gene Expression Regulation, Neoplastic , Genes, Dominant , Glioblastoma/pathology , Glioma/metabolism , Glioma/pathology , Humans , Mice , Neoplasm Transplantation , Phenotype , Phosphorylation , Pseudopodia/metabolism , RNA, Small Interfering/metabolism , ras GTPase-Activating Proteins/metabolismABSTRACT
Schwannomas are common peripheral nerve sheath tumors that can cause debilitating morbidities. We performed an integrative analysis to determine genomic aberrations common to sporadic schwannomas. Exome sequence analysis with validation by targeted DNA sequencing of 125 samples uncovered, in addition to expected NF2 disruption, recurrent mutations in ARID1A, ARID1B and DDR1. RNA sequencing identified a recurrent in-frame SH3PXD2A-HTRA1 fusion in 12/125 (10%) cases, and genomic analysis demonstrated the mechanism as resulting from a balanced 19-Mb chromosomal inversion on chromosome 10q. The fusion was associated with male gender predominance, occurring in one out of every six men with schwannoma. Methylation profiling identified distinct molecular subgroups of schwannomas that were associated with anatomical location. Expression of the SH3PXD2A-HTRA1 fusion resulted in elevated phosphorylated ERK, increased proliferation, increased invasion and in vivo tumorigenesis. Targeting of the MEK-ERK pathway was effective in fusion-positive Schwann cells, suggesting a possible therapeutic approach for this subset of tumors.